ONO4817 is a selective serotonin and dopamine reuptake inhibitor developed as an antidepressant for the treatment of major depressive disorder. This category encompasses the parent drug and its specific… Read more
ONO4817 is a selective serotonin and dopamine reuptake inhibitor developed as an antidepressant for the treatment of major depressive disorder. This category encompasses the parent drug and its specific stereoisomers, which serve as essential pharmaceutical reference standards during drug development. Laboratories rely on these high-quality compounds to support rigorous analytical testing, including chiral separation, stereoisomer identification, and purity assessment. By providing authentic samples for method validation and impurity profiling, these materials help ensure the precision and reliability of quality control processes. Access to these reference compounds is vital for researchers and analytical chemists conducting stability studies or quantifying trace levels of related substances, allowing for accurate characterization throughout the lifecycle of the active pharmaceutical ingredient.